Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists.
Quick Facts
What This Study Found
The review covers several strategies for oral peptide delivery using lipid nanocarriers:
- Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) protect peptides from enzymatic degradation
- Absorption enhancers can be incorporated to improve gut membrane permeability
- PEGylation of nanocarriers improves stability and circulation time
- Lipidization (adding fatty acid chains to peptides) improves membrane interaction
Animal studies have shown significant hypoglycemic (blood sugar lowering) activity and safety for lipid nanocarrier-delivered insulin and GLP-1 agonists. However, translating these results to humans has been a persistent challenge.
The review also discusses the clinical status of various nanocarrier approaches for anti-diabetic peptides, noting that few have advanced to human trials.
Key Numbers
SLNs, NLCs, liposomes; absorption enhancers, PEGylation, lipidization; animal hypoglycemic activity confirmed; few human trials
How They Did This
Narrative review of lipid nanocarrier technologies for oral delivery of insulin and GLP-1 receptor agonists, covering formulation strategies, absorption enhancement mechanisms, animal study results, and clinical development status.
Why This Research Matters
Diabetes requires lifelong treatment, and most peptide-based therapies require injections. Making insulin and GLP-1 drugs available as pills would dramatically improve patient compliance and quality of life. Lipid nanocarriers are one of the most promising platforms for achieving this.
What This Study Doesn't Tell Us
This is a review without new data. Most lipid nanocarrier work is in animal models, and human translation has been difficult. Manufacturing scalability and cost are not addressed. Regulatory pathways for nanomedicine-based oral peptides are complex and uncertain.
Trust & Context
- Original Title:
- Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists.
- Published In:
- Journal of drug targeting, 29(8), 834-847 (2021)
- Authors:
- Poudwal, Swapna, Misra, Ambikanandan, Shende, Pravin(2)
- Database ID:
- RPEP-05693
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05693APA
Poudwal, Swapna; Misra, Ambikanandan; Shende, Pravin. (2021). Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists.. Journal of drug targeting, 29(8), 834-847. https://doi.org/10.1080/1061186X.2021.1894434
MLA
Poudwal, Swapna, et al. "Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists.." Journal of drug targeting, 2021. https://doi.org/10.1080/1061186X.2021.1894434
RethinkPeptides
RethinkPeptides Research Database. "Role of lipid nanocarriers for enhancing oral absorption and..." RPEP-05693. Retrieved from https://rethinkpeptides.com/research/poudwal-2021-role-of-lipid-nanocarriers
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.